Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Timing matters: automatic rebalancing should occur as your allocations drift beyond set thresholds.
18,157 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Solmate plans a reverse stock split to fund a Solana-focused hub in the UAE, part of a broader pivot that includes ex...
The iShares MSCI Japan ETF is at the center of a major market overhaul in Japan, delivering broad exposure to a shift...
Salesforce surged Thursday as the company announced a major debt offering to back a sizable share repurchase plan. Th...
When the broader market stumbled, CoreWeave stock surged higher this week thanks to AI cloud demand and solid custome...
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Chase has cut credit-card limits for some customers with minimal usage, raising questions about credit-score impact a...
A January 12, 2026 bill aims to ban lawmakers and families from buying stocks, with public notice and hefty penalties...
In 2026, a disciplined trio of growth ETFs offers a clear path to long-term wealth through earnings-driven expansion,...
As dxlg posts its 2025 numbers, investors should focus on sales trends, margins, and cash flow. This guide breaks dow...
A major logistics stock drops after a surprising accounting error, sending shockwaves through the market. This articl...
Navitas Semiconductor is pursuing an AI data-center power strategy built around 800V architecture. This move could re...